Introduction
============

Anaplastic thyroid carcinoma (ATC) is a rare but aggressive thyroid carcinoma in humans with an estimated incidence of 1--2 cases per million people in the USA. It comprises only 1--2% of all thyroid cancers and accounts for 3.6% of all human cancers ([@ref-2]; [@ref-30]; [@ref-4]). Unlike well-differentiated thyroid carcinoma diagnosed by fine-needle aspiration, ATC is diagnosed by clinical manifestations including rapidly growing thyroid mass, dyspnea and so on ([@ref-7]). Half of the patients exhibited distant metastasis at the time of diagnosis ([@ref-6]). ATC is almost lethal with the median OS of the patients from the time of diagnosis reported to be 3--5 months ([@ref-12]). Most death of ATC patients is attributable to rapid progression of tumor which often results in suffocation ([@ref-33]). Significant independent predictors reported to be associated with poorer survival in ATC are advanced stage, older age, distant metastases, large primary tumor size and elevated white blood count, while better prognosis has been observed when ATC coexists with differentiated thyroid carcinoma ([@ref-24]; [@ref-25]; [@ref-14]). Current treatments for ATC include surgery, chemotherapy and radiotherapy, and the optional therapy tailored to each patient depends on their own risk estimation ([@ref-5]). Considering the aggressive behavior of this disease, prompt assessments of the patients are desirable in order to make a specific management plan.

Because of the need of precise risk evaluation of ATC patients and the lack of a specific and practical predictive tool, establishing a predictive model that incorporates numerous predictors related to the probability of OS and CSS becomes desirable. Among all the available models, a nomogram can provide an evidence-based, individualized, highly precise risk evaluation ([@ref-37]). Nomograms are widely used among several kinds of diseases, such as gallbladder cancer ([@ref-36]), Crohn's disease ([@ref-40]), non-small cell lung cancer ([@ref-38]) and so on. Therefore, the purpose of this study is to identify the most relevant prognosticators and combine them into nomograms to better define the risk factors of an individual patient.

Methods
=======

Study population
----------------

Cases diagnosed as anaplastic thyroid cancer during 1983--2013 were extracted from the Surveillance, Epidemiology and End Results (SEER-18) registries ([@ref-22]). It includes data from 18 high-quality registries, which represents about 26% of the US population. Information about demographic, tumor characteristics and treatment for each case were obtained from the medical record. We identified anaplastic thyroid cancer patients using the International Classification of Diseases for Oncology, Third Edition (ICD-O-3). Consistent with previous research ([@ref-18]), only patients with ICD-O-3 histologic codes of 8020--8035 and topography code of C73 were included. Missing data including patients' unknown race, radiation treatment and survival time were imputed with multiple imputations. We carried out multiple imputations based on R version 3.5.1 using the R package of mice. Then patients were excluded if they were not first malignant primary and had undefined surgery. We divided our data into internal validation and external validation ([Fig. 1](#fig-1){ref-type="fig"}).

![Flow chart for selection the data from SEER database.](peerj-08-9173-g001){#fig-1}

Covariates
----------

The demographics of patients (age, sex, race and year of diagnosis), tumor characteristics (SEER historic stage A and tumor size) and treatment (surgery and radiotherapy) were gathered from the database. Patients were divided into \<65 and ≥65 years old groups according to age at diagnosis. We have used splines to explore non-linear relationships between age at diagnosis and survival months. The result was shown as[Fig. S1](#supp-1){ref-type="supplementary-material"}. As shown in the figure, survival months of patients exhibited a steep decline between 60 and 80 years old. It's obvious that the age in this range is related to the survival months which was coherent with numerous studies. Some studies reported that age ≥70 years old was an indicator of poor survival for ATC patients ([@ref-23]; [@ref-33]). Some studies reported that people younger than 60 years old had superior prognosis ([@ref-1]; [@ref-27]). Taken these into consideration, we divided patients into \<65 and ≥65 years old groups. SEER historic stage A was an indicator to distinguish tumor stage: localized (confined to thyroid), regional (tumor extend to adjacent tissues, blood vessels and lymph nodes), distant (distant metastasis) and unstaged. Only after 1983, SEER database began to record tumor size. So far, there were 3 codes to identify tumor size: extent of disease-4 codes (EOD-4) for 1983--1987, extent of disease-10 codes (EOD-10) for 1988--2003, and collaborative staging codes (CS) for 2004--2013. We combined these codes to define tumor size in patients with anaplastic thyroid cancer. Furthermore, patients were divided into lobectomy, total/near total thyroidectomy and no cancer-direct surgery/unknown groups according to the surgical procedure.

Outcomes
--------

In this study, the outcomes we were interested in were overall survival (OS) and cancer-specific survival (CSS), which were defined as the interval from diagnosis until death for all causes and the interval from diagnosis until death only due to this tumor, respectively. SEER database provides specific codes to define both outcomes.

Data analysis
-------------

Only the first matching record was selected into analysis. The Kaplan--Meier method was used to compare OS and CSS between each covariate, and their differences were assessed by log-rank test. Multivariate Cox regression analysis was used to determine the independent risk factors of OS and CSS for anaplastic thyroid cancer patients through the SPSS statistical software (version 24). Besides, as various cause-specific deaths were competing risk events, we also used competing risk analyses as additional analyses to make our results more credible. We carried out competing risk analyses using the R package of cmprsk ([@ref-29]). All independent risk factors analyzed by multivariate Cox regression were included to construct the nomograms.

Nomograms were built and validated by R version 3.5.1, using the R package of rms and survival ([@ref-3]). We used bootstrap self-sample verification while establishing nomogram prediction model based on the data calculated by multivariate logistic regression analysis. Internal calibration and external calibration curves were used to assess the accuracy of the nomograms. To create a calibration diagram, we used Cox regression predictive model. *X*-axis means predictive survival time and *Y*-axis means actual survival time. In a perfectly predictive model, predictive rates would fall on a 45° diagonal line. We used concordance index (C-index) to describe the discrimination between predicted probability and actual outcome. The value of the C-index should fall between 0.5 and 1.0, with 0.5 presenting random chance and 1.0 presenting a perfect accordance. Generally, the value greater than 0.7 indicated a strong predictive ability. To evaluate the accuracy and practicability of our nomogram, we carried out receiver operating characteristic (ROC) analysis and Decision Curve Analysis (DCA) based on the R package of survival ROC and rmda respectively ([@ref-28]). ROC represented sensitivity and specificity of nomogram while couldn't ignore false positive rate and false negative rate. DCA represented net benefit of a clinical decision. To compare the accuracy of our nomogram with that of traditional TNM staging system, the net reclassification index (NRI) and integrated discrimination index (IDI) were analyzed based on the R package of nricens and predictABEL as reported ([@ref-39]).

A two-sided *P* value of 0.05 was considered statistically significant. The Kaplan--Meier curves were built by GraphPad Prism 6.0.

Results
=======

Patient characteristics
-----------------------

A total of 1,404 patients diagnosed as ATC during 1983--2013 was included in the analysis. We divided our patients into two parts: internal validation and external validation. Internal validation contained patients diagnosed from 2000 to 2013, and external validation contained patients diagnosed from 1983 to 1999. Demographic, tumor characteristics and treatment information of patients in internal validation were presented in [Table 1](#table-1){ref-type="table"} (Year of diagnosis of patients in external validation ranged from 1983--1999). Elder (654 (64.5%)), female (630 (62.1%)) and white patients (815 (80.4%)) constituted the main part of the cases. Median age at diagnosis of cases was 70 years old and median follow-up time was 2 months. Most patients (567 (56.1%)) underwent tumor metastasis, while only 61 (6.0%) patients had localized tumors. When stratifying by tumor size, more than half of the patients had a tumor size greater than 4 cm. In addition, of the patients who underwent surgery, 177 (17.5%) cases underwent lobectomy and 287 (28.3%) cases underwent total or near total thyroidectomy. And 571 (56.3%) patients received radiotherapy.
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###### Demographics, tumor characteristics and treatment information of 1014 patients with anaplastic thyroid carcinoma.
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  Characteristics            Internal validation   External validation         
  -------------------------- --------------------- --------------------- ----- ------
  Age group                                                                    
  \<65                       360                   35.5                  123   31.5
  ≥65                        654                   64.5                  267   68.5
  Sex                                                                          
  Male                       384                   37.9                  145   37.2
  Female                     630                   62.1                  245   62.8
  Race                                                                         
  White                      815                   80.4                  321   82.3
  Black                      84                    8.3                   23    5.9
  Others                     115                   11.3                  46    11.8
  Year of diagnosis                                                            
  2000--2004                 311                   30.7                        
  2005--2009                 367                   36.2                        
  2010--2013                 336                   33.1                        
  SEER historic stage A                                                        
  Localized                  61                    6.0                   31    7.9
  Regional                   337                   33.2                  155   39.7
  Distant                    569                   56.1                  166   42.6
  Unstaged                   47                    4.6                   38    9.7
  Tumor size                                                                   
  ≤2.0 cm                    31                    3.1                   19    4.9
  2.1--4.0 cm                115                   11.3                  36    9.2
  \>4 cm                     573                   56.5                  162   41.5
  Unknown                    295                   29.1                  173   44.4
  Surgery                                                                      
  Lob                        177                   17.5                  68    17.4
  Total thy                  287                   28.3                  84    21.5
  No cancer-direct/Unknown   550                   54.2                  238   61.0
  Radiotherapy                                                                 
  No                         443                   43.7                  133   34.1
  Yes                        571                   56.3                  257   65.9

**Note:**

Lob, Lobectomy; Thy, Thyroidectomy.

Survival analysis
-----------------

The Kaplan--Meier analysis ([Figs. 2](#fig-2){ref-type="fig"} and [3](#fig-3){ref-type="fig"}) showed age ≥65 years old rather than age \<65 years old was significantly associated with worse OS and CSS for patients with ATC. It also revealed that sex and race was not significantly associated with OS and CSS. When considering year of diagnosis, we found that patients diagnosed from 2010 to 2013 had worst survival. When stratifying by tumor stage, ATC with distant metastasis showed severely poorer OS and CSS than a localized or regional tumor. The results also indicated ATC with larger tumor size had significantly worse survival. OS and CSS were significantly better for patients who underwent total or near total thyroidectomy than those who underwent lobectomy, while patients with no cancer-direct surgery or unknown surgical procedure had the worst survival. As for radiotherapy, survival was better for patients receiving radiotherapy than patients who did not receive radiotherapy.

![Overall survival of patients with ATC by different variables.\
(A) Age, (B) sex, (C) race, (D) year of diagnosis, (E) SEER historic stage A, (F) tumor size, (G) surgery and (H) radiotherapy. Total/Near, Total thyroidectomy/Near thyroidectomy; NCDS, No cancer-direct surgery.](peerj-08-9173-g002){#fig-2}

![Cancer-specific survival of patients with ATC by different variables.\
(A) Age, (B) sex, (C) race, (D) year of diagnosis, (E) SEER historic stage A, (F) tumor size, (G) surgery and (H) radiotherapy. Total/Near, Total thyroidectomy/Near thyroidectomy; NCDS, No cancer-direct surgery.](peerj-08-9173-g003){#fig-3}

Independent factors associated with OS and CSS
----------------------------------------------

The Cox proportional hazards regression analysis was used to determine independent risk factors for OS ([Table 2](#table-2){ref-type="table"}), and Cox proportional hazards and competing risk analyses were used to determine independent risk factors for CSS ([Table 3](#table-3){ref-type="table"}). In our study, age ≥65 years old was a risk factor with worse OS (HR, 1.525; (95% CI \[1.326--1.752\]); *P* \< 0.001). The results also indicated that tumor stage (distant vs localized: HR, 2.641; (95% CI \[1.923--3.628\]); *P* \< 0.001); regional vs localized: HR, 1.427; (95% CI \[1.031--1.974\]); *P* = 0.032, unstaged vs localized: HR, 2.138; (95% CI \[1.393--3.282\]; *P* = 0.001), tumor size (unknown vs ≤2.0 cm: HR, 1.647; (95% CI \[1.115--2.433\]); *P* = 0.012), surgery (total/near total thyroidectomy vs lobectomy: HR, 0.715; (95% CI \[0.583--0.878\]); *P* = 0.001; no cancer-direct surgery/unknown vs lobectomy: HR, 1.702; (95% CI \[1.420--2.040\]); *P* \< 0.001) and radiotherapy (yes vs no: HR, 0.508; (95% CI \[0.445--0.580\]); *P* \< 0.001). Besides, sex, race and year of diagnosis were not significantly associated with survival of patients. And after adjusting for other available variables, age ≥65 years old was independently associated with worse OS (HR, 1.471; (95% CI \[1.276--1.696\]); *P* \< 0.001) and tumor size, surgery and radiotherapy were also independent risk factors. As for CSS ([Table 3](#table-3){ref-type="table"}), we found that age, stage, surgery and radiotherapy were risk factors according to univariate survival analysis. After adjusting for other available variables, we found that age ≥65 years old was an independent risk factor with worse CSS (HR, 1.408; (95% CI \[1.216--1.631\]); *P* \< 0.001), which was consistent with the results of competing risk analysis (HR, 1.205; (95% CI \[1.053--1.379\]); *P* \< 0.01). Similar to age, stage, surgery and radiotherapy were also independent risk factors according to both multivariate survival analysis and competing risk analysis. While sex, race, year of diagnosis and tumor size were not associated with prognosis of ATC patients.
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###### Cox proportional hazards regression analysis of overall survival.
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  Characteristics            Univariate analysis      *P*       Multivariate analysis    *P*
  -------------------------- ------------------------ --------- ------------------------ ---------
  Age group                                                                              
  \<65                       1.00 (reference)                   1.00 (reference)         
  ≥65                        1.525 \[1.326--1.752\]   \<0.001   1.471 \[1.276--1.696\]   \<0.001
  Sex                                                                                    
  Male                       1.00 (reference)                   1.00 (reference)         
  Female                     1.065 \[0.931--1.218\]   0.357     1.032 \[0.900--1.184\]   0.651
  Race                                                                                   0.614
  White                      1.00 (reference)                   1.00 (reference)         
  Black                      1.166 \[0.921--1.474\]   0.202     1.070 \[0.844--1.358\]   0.576
  Others                     1.253 \[1.023--1.535\]   0.029     1.097 \[0.892--1.348\]   0.382
  Year of diagnosis                                                                      0.573
  2000--2004                 1.00 (reference)                   1.00 (reference)         
  2005--2009                 0.907 \[0.775--1.063\]   0.229     0.932 \[0.790--1.100\]   0.405
  2010--2013                 1.044 \[0.885--1.230\]   0.611     1.009 \[0.849--1.199\]   0.922
  SEER historic stage A                                                                  
  Localized                  1.00 (reference)                   1.00 (reference)         
  Regional                   1.427 \[1.031--1.974\]   0.032     1.506 \[1.086--2.088\]   0.014
  Distant                    2.641 \[1.923--3.628\]   \<0.001   2.285 \[1.655--3.156\]   \<0.001
  Unstaged                   2.138 \[1.393--3.282\]   0.001     1.272 \[0.816--1.982\]   0.288
  Tumor size                                                                             0.015
  ≤2.0 cm                    1.00 (reference)                   1.00 (reference)         
  2.1--4.0 cm                0.964 \[0.633--1.466\]   0.863     0.848 \[0.555--1.297\]   0.447
  \>4 cm                     1.144 \[0.781--1.674\]   0.490     0.884 \[0.601--1.301\]   0.532
  Unknown                    1.647 \[1.115--2.433\]   0.012     1.139 \[0.760--1.705\]   0.529
  Surgery                                                                                \<0.001
  Lob                        1.00 (reference)                   1.00 (reference)         
  Total thy                  0.715 \[0.583--0.878\]   0.001     0.802 \[0.651--0.987\]   0.037
  No cancer-direct/Unknown   1.702 \[1.420--2.040\]   \<0.001   1.492 \[1.231--1.807\]   \<0.001
  Radiotherapy                                                                           
  No                         1.00 (reference)                   1.00 (reference)         
  Yes                        0.508 \[0.445--0.580\]   \<0.001   0.533 \[0.465--0.611\]   \<0.001
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###### Cox proportional hazards regression analysis and competing risk analysis of cancer-specific survival.
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  Characteristics            Univariate analysis      *P*       Multivariate analysis    *P*       Competing risk analysis   *P*
  -------------------------- ------------------------ --------- ------------------------ --------- ------------------------- --------
  Age group                                                                                                                  
  \<65                       1.00 (reference)                   1.00 (reference)                   1.00 (reference)          
  ≥65                        1.464 \[1.268--1.691\]   \<0.001   1.408 \[1.216--1.631\]   \<0.001   1.205 \[1.053--1.379\]    \<0.01
  Sex                                                                                                                        
  Male                       1.00 (reference)                   1.00 (reference)                   1.00 (reference)          
  Female                     1.086 \[0.944--1.248\]   0.249     1.067 \[0.924--1.230\]   0.377     1.123 \[0.979--1.289\]    0.10
  Race                                                                                   0.812                               
  White                      1.00 (reference)                   1.00 (reference)                   1.00 (reference)          
  Black                      1.139 \[0.891--1.457\]   0.299     1.051 \[0.819--1.349\]   0.695     1.005 \[0.767--1.317\]    0.97
  Others                     1.193 \[0.963--1.479\]   0.106     1.064 \[0.855--1.324\]   0.579     1.057 \[0.840--1.330\]    0.64
  Year of diagnosis                                             0.388                                                        
  2000--2004                 1.00 (reference)                   1.00 (reference)                   1.00 (reference)          
  2005--2009                 0.879 \[0.745--1.036\]   0.124     0.905 \[0.762--1.074\]   0.254     0.88 \[0.744--1.042\]     0.14
  2010--2013                 1.034 \[0.872--1.225\]   0.703     1.004 \[0.840--1.200\]   0.967     0.993 \[0.838--1.176\]    0.93
  SEER historic stage A                                         \<0.001                                                      
  Localized                  1.00 (reference)                   1.00 (reference)                   1.00 (reference)          
  Regional                   1.549 \[1.087--2.206\]   0.015     1.625 \[1.138--2.319\]   0.008     1.606 \[1.146--2.250\]    \<0.01
  Distant                    2.974 \[2.105--4.202\]   \<0.001   2.580 \[1.816--3.665\]   \<0.001   2.407 \[1.723--3.362\]    \<0.01
  Unstaged                   2.448 (1.553 to 3.856)   \<0.001   1.460 (0.913 to 2.335)   0.114     1.625 (1.035 to 2.552)    0.04
  Tumor size                                                                             0.024                               
  ≤2.0 cm                    1.00 (reference)                   1.00 (reference)                   1.00 (reference)          
  2.1--4.0 cm                1.002 \[0.644--1.559\]   0.993     0.879 \[0.562--1.374\]   0.571     1.027 \[0.672--1.571\]    0.90
  \>4 cm                     1.184 \[0.791--1.771\]   0.411     0.902 \[0.600--1.357\]   0.622     0.985 \[0.657--1.475\]    0.94
  Unknown                    1.715 \[1.136--2.590\]   0.010     1.162 \[0.759--1.778\]   0.49      1.185 \[0.778--1.806\]    0.43
  Surgery                                                                                \<0.001                             
  Lob                        1.00 (reference)                   1.00 (reference)                   1.00 (reference)          
  Total Thy                  0.705 \[0.570--0.873\]   0.001     0.782 (0.630 to 0.971)   0.026     0.774 (0.641 to 0.936)    \<0.01
  No cancer-direct/Unknown   1.703 \[1.411--2.055\]   \<0.001   1.461 (1.198 to 1.782)   \<0.001   1.252 (1.046 to 1.499)    0.01
  Radiotherapy                                                                                                               
  No                         1.00 (reference)                   1.00 (reference)                   1.00 (reference)          
  Yes                        0.532 \[0.463--0.611\]   \<0.001   0.558 \[0.484--0.644\]   \<0.001   0.718 \[0.624--0.825\]    \<0.01

**Note:**

Lob, Lobectomy; Thy, Thyroidectomy.

Nomogram construction and validation
------------------------------------

All independent risk factors derived from Cox proportional hazards regression analysis were used to construct the nomograms, which were effective tools to predict 6-month, 1-year and 2-year OS or CSS ([Fig. 4](#fig-4){ref-type="fig"}). Therefore, age group, tumor stage, tumor size, surgery and radiotherapy were included in the nomogram for OS and CSS. Both for OS and CSS, tumor stage contributed most for survival. Using the nomograms to assess the prognosis of a patient requires adding the scores corresponding to each predictor to get a total score. The total score corresponds to 6-month, 1-year, 2-year overall or CSS rate.

![Nomograms for predicting 6-month, 1-year, 2-year OS and CSS rates of patients with ATC.\
(A) Predicting 6-month, 1-year, 2-year OS and (B) predicting 6-month, 1-year, 2-year CSS. NCDS, No cancer-direct surgery.](peerj-08-9173-g004){#fig-4}

The nomograms were validated internally and externally. The C-index values of internal validation were 0.765 for OS and 0.773 for CSS, respectively, indicating acceptable discriminations. In addition, the calibration curves for OS and CSS demonstrated great accordance between predicted survival by nomogram and actual observed survival. Internal calibration curves ([Fig. 5](#fig-5){ref-type="fig"}) and external calibration ([Fig. 6](#fig-6){ref-type="fig"}) curves suggested that our nomograms had proper calibrations.

![The internal calibration curves of the nomogram predicting 6-month, 1-year, 2-year OS and CSS.\
*X*-axis represents the nomogram predicted survival, and *Y*-axis represents the actual survival. (A) Calibration curve of nomogram predicting 6-month OS, (B) calibration curve of nomogram predicting 1-year OS, (C) calibration curve of nomogram predicting 2-year OS, (D) calibration curve of nomogram predicting 6-month CSS, (E) calibration curve of nomogram predicting 1-year CSS and (F) calibration curve of nomogram predicting 2-year CSS.](peerj-08-9173-g005){#fig-5}

![The external calibration curves of the nomogram predicting 6-month, 1-year, 2-year OS and CSS.\
*X*-axis represents the nomogram predicted survival, and *Y*-axis represents the actual survival. (A) Calibration curve of nomogram predicting 6-month OS, (B) calibration curve of nomogram predicting 1-year OS, (C) calibration curve of nomogram predicting 2-year OS, (D) calibration curve of nomogram predicting 6-month CSS, (E) calibration curve of nomogram predicting 1-year CSS and (F) calibration curve of nomogram predicting 2-year CSS.](peerj-08-9173-g006){#fig-6}

To evaluate accuracy of our nomograms, we analyzed ROC curves. The ROC curves indicated sensitivity and specificity of a clinical evaluating model. The *Y*-axis meant sensitivity and the *X*-axis meant false positive rate. Because TNM was an acknowledged clinical prognostic factor and age was a risk factor related to ATC, we compared our nomograms with the accuracy of TNM and age evaluations. The ROC curves of 6-month, 1-year, 2-year nomograms for OS and CSS were all superior to TNM and age evaluations ([Fig. 7](#fig-7){ref-type="fig"}). To assess the practicability of our nomograms, we analyzed DCA ([Fig. 8](#fig-8){ref-type="fig"}). DCA represented net benefits of clinical decisions. The *Y*-axis meant net benefit and the *X*-axis meant high risk threshold. The horizontal gray line meant all true negative rate and diagonal gray line meant all true positive rate. DCA suggested that nomogram for OS was superior to TNM and age evaluations, while nomogram for CSS was similar to TNM evaluation but superior to age evaluations. Furthermore, our model exhibited better discrimination compared based on NRI and IDI. The NRI for the 6-, 12- and 24-month follow-up examinations were 0.593 (95% CI \[0.393--0.781\]), 0.589 (95% CI \[0.353--0.786\]) and 0.473 (95% CI \[0.103--0.705\]), respectively. Similarly, the IDI for the 6-, 12- and 24-month follow-up examinations were 0.105 (*P* \< 0.001), 0.092 (*P* \< 0.001) and 0.061 (*P* \< 0.001), respectively. Both NRI and IDI indicated a superior predictive ability of our model compared to TNM staging system.

![The ROC curves of the nomogram predicting 6-month, 1-year, 2-year OS and CSS.\
*X*-axis represents false positive rate, and *Y*-axis represents sensitivity. (A) ROC curve of the nomogram predicting 6-month OS, (B) ROC curve of the nomogram predicting 1-year OS, (C) ROC curve of the nomogram predicting 2-year OS, (D) ROC curve of the nomogram predicting 6-month CSS, (E) ROC curve of the nomogram predicting 1-year CSS and (F) ROC curve of the nomogram predicting 2-year CSS.](peerj-08-9173-g007){#fig-7}

![The DCA curves of the nomogram compared with prognosis based on TNM staging.\
*X*-axis represents high risk threshold and *Y*-axis represents net benefit. (A) DCA curve of the nomogram predicting OS compared with prognosis based on TNM staging. (B) DCA curve of the nomogram predicting CSS compared with prognosis based on TNM staging.](peerj-08-9173-g008){#fig-8}

Discussion
==========

ATC is a rare and typically aggressive malignant tumor with a poor prognosis. Though ATC is lethal, there are many other causes patients could die from including complications of local or distant diseases. Therefore, it's necessary to build prognostic predictive models designed for the individual patient. Among all the predictive tools, nomogram performs well in predicting survival for many cancers ([@ref-10]). Several reports haven shown that nomograms are scientific and precise enough to make themselves an alternative standard which can compare to the traditional TNM staging systems ([@ref-35]; [@ref-20]). Thus, the aim of this study was to develop the OS and CSS nomograms to precisely predict the survival of patients with ATC.

In our study, females and Whites are predominant risk factors with a female to male ratio of 1.67:1 and Whites to non-Whites ratio of 4.33:1, which were consistent with previous reports ([@ref-12]). Additionally, above half of the samples exhibited distant metastasis, similar to what has been reported before ([@ref-6]). As for the year of diagnosis, we could see an increasing trend year by year although it has been reported that there was no obvious change in the incidence of ATC ([@ref-2]), even some data showed that the relative incidence of ATC has gradually decreased over time ([@ref-17]). This interesting trend might be attributable to increased use of ultrasonography and popularity of physical examination in recent years, reduction of incidence of goiter which was highly relevant to ATC via increasing in dietary iodine content.

Several studies have identified numerous factors including age, gender, clinical manifestation, tumor size, distant metastasis, leukocytosis, and acute symptoms as prognostic factors for ATC ([@ref-26]; [@ref-17]). In our study, besides the factors mentioned above, we investigated several uncommon indicators such as year of diagnosis, historic stage, treatment modality (surgery and radiotherapy). For each risk factor, we used multivariate analysis, survival analysis, Cox regression analysis and competing risk analysis to obtain accurate conclusions. We found that historic stage was the most important prognostic factors among all the indicators as the risk of mortality for patients with distant metastasis was 2.285 times that of patients with localized primary tumors, which was parallel to previous studies ([@ref-15]; [@ref-11]; [@ref-16]). Furthermore, the prognosis of people older than 65 was worse than that of people younger than 65 in our nomogram which was consistent with previous reports ([@ref-27]; [@ref-21]; [@ref-9]; [@ref-33]).

The acute onset and rapid progress of ATC required a timely systematic and appropriate treatment plan for patients. And the appropriate treatment options recommended in American Thyroid Association (ATA) guidelines published in 2012 included surgery, radiotherapy and chemotherapy and the final therapy chosen for each patient should be based on their own conditions ([@ref-31]). Our results also showed a better prognosis in patients undertaking complete thyroid surgical resections compared with those patients who didn't undergo surgery. What's more, radiotherapy in ATC patients was associated with an improved OS and CSS in our study. It was consistent with what Minoru Kihara has found in his study that the prognosis of the patients with ATC depended on whether complete resection could be achieved ([@ref-13]). [@ref-12] showed in their study that combined surgical resection with external beam radiation treatment were associated with a better survival in patients with regional and distant disease. Another study conducted by Demeter JG et al. also reported that both operation and radiotherapy in ATC patients improved survival ([@ref-34]). However, our data didn't include information about chemotherapy, so it was hard to tell how chemotherapy effected prognosis of ATC patients. In other researches, it has been reported that patients who received radiotherapy and chemotherapy had a significant advantaged survival ([@ref-19]).

Although it has been reported that small tumors indicated better prognosis ([@ref-33]), we found that tumor size was not associated with prognosis of ATC patients. The interesting contradiction was attributable to specific tumor size. Tumor sizes less than or equal to 5--7 cm were favorable prognostic indicators of ATC. However, we studied tumor sizes less than 4 cm. As for gender, some studies reported no effects from gender on survival ([@ref-8]; [@ref-32]; [@ref-13]), some studies reported that gender was an independent prognostic factor ([@ref-27]). In the current study, we discovered that gender was not a prognostic factor in CSS and OS. A reasonable explanation for this was that many other causes could result in the deaths of ATC patients such as complications of local or distant diseases which counteracted the role of sex ([@ref-7]). In addition, race and year of diagnosis had no effects on prognosis of ATC patients.

Nomogram is a user-friendly personalized prognostic tool that is useful for counseling patients, assisting the therapeutic decision-making process. To the best of our knowledge, our study was the first nomogram to estimate the OS and CSS of patients with ATC. Our model was reliable because of good C-index, calibration curves and ROC curves of internal validation and external validations which can support the accuracy of our model. Besides, DCA indicated that our nomograms had good practicability.

However, we had to admit that there were some limitations in our study. First of all, the cases included in our study was not big enough (1,404). What's more, because the SEER database didn't contain information regarding other thyroid diseases, we couldn't evaluate the effects of these factors. Unfortunately, these factors played important roles in prognosis of ATC patients. For example, most of ATC patients had a history of goiter which was thought to be a risk factor for survival ([@ref-21]). Finally, the unavoidable selection bias did exist in all retrospective studies. We hoped that more future studies or research could be conducted to confirm our findings.

In summary, we identified age, surgery, radiotherapy, historic stage as prognostic predictor for the OS and CSS of patients with ATC. We also developed and validated prognostic nomogram for ATC, which we recommend using in patients with ATC to assist predicting the survival of the patients.
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###### Spline plots for examination of non-linear relationships between age at diagnosis and survival months.

*X*-axis represents age at diagnosis and *Y*-axis represents survival months.

###### 

Click here for additional data file.
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